The global Long-acting DPP-4 Inhibitor Drug market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.

Long-acting dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of drugs used to treat type 2 diabetes. They are characterized by a long half-life and extended duration of action, with some formulations allowing for once-weekly dosing and others even every two weeks.

From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Long-acting DPP-4 Inhibitor Drug leading manufacturers including Merck & Co, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, Haisco Pharmaceutical, Easton Biopharmaceuticals, Baiji Dichang Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Merck & Co leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting DPP-4 Inhibitor Drug market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Long-acting DPP-4 Inhibitor Drug Market Report

Report Metric	Details
Report Name	Long-acting DPP-4 Inhibitor Drug Market
Segment by Type	Weekly Biweekly
Segment by Application	Hospital Clinic Others
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck & Co, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, Haisco Pharmaceutical, Easton Biopharmaceuticals, Baiji Dichang Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Long-acting DPP-4 Inhibitor Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Long-acting DPP-4 Inhibitor Drug Market report?

Ans: The main players in the Long-acting DPP-4 Inhibitor Drug Market are Merck & Co, Takeda Pharmaceutical, Furiex, Beacon Pharma, Kelun Pharmaceutical, Haisco Pharmaceutical, Easton Biopharmaceuticals, Baiji Dichang Pharmaceutical

What are the Application segmentation covered in the Long-acting DPP-4 Inhibitor Drug Market report?

Ans: The Applications covered in the Long-acting DPP-4 Inhibitor Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Long-acting DPP-4 Inhibitor Drug Market report?

Ans: The Types covered in the Long-acting DPP-4 Inhibitor Drug Market report are Weekly, Biweekly

1 Study Coverage

1.1 Introduction to Long-acting DPP-4 Inhibitor Drug: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Weekly

1.2.3 Biweekly

1.3 Market Segmentation by Application

1.3.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Long-acting DPP-4 Inhibitor Drug Revenue Estimates and Forecasts 2020-2031

2.2 Global Long-acting DPP-4 Inhibitor Drug Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Long-acting DPP-4 Inhibitor Drug Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Long-acting DPP-4 Inhibitor Drug Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Weekly Market Size by Players

3.3.2 Biweekly Market Size by Players

3.4 Global Long-acting DPP-4 Inhibitor Drug Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Long-acting DPP-4 Inhibitor Drug Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Long-acting DPP-4 Inhibitor Drug Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Long-acting DPP-4 Inhibitor Drug Market Size by Type (2020-2031)

6.4 North America Long-acting DPP-4 Inhibitor Drug Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Long-acting DPP-4 Inhibitor Drug Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Type (2020-2031)

7.4 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Type (2020-2031)

8.4 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Long-acting DPP-4 Inhibitor Drug Market Size by Type (2020-2031)

9.4 Central and South America Long-acting DPP-4 Inhibitor Drug Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Long-acting DPP-4 Inhibitor Drug Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Long-acting DPP-4 Inhibitor Drug Market Size by Type (2020-2031)

10.4 Middle East and Africa Long-acting DPP-4 Inhibitor Drug Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Merck & Co

11.1.1 Merck & Co Corporation Information

11.1.2 Merck & Co Business Overview

11.1.3 Merck & Co Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.1.4 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.1.5 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue by Product in 2024

11.1.6 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue by Application in 2024

11.1.7 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue by Geographic Area in 2024

11.1.8 Merck & Co Long-acting DPP-4 Inhibitor Drug SWOT Analysis

11.1.9 Merck & Co Recent Developments

11.2 Takeda Pharmaceutical

11.2.1 Takeda Pharmaceutical Corporation Information

11.2.2 Takeda Pharmaceutical Business Overview

11.2.3 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.2.4 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.2.5 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Product in 2024

11.2.6 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Application in 2024

11.2.7 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Geographic Area in 2024

11.2.8 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug SWOT Analysis

11.2.9 Takeda Pharmaceutical Recent Developments

11.3 Furiex

11.3.1 Furiex Corporation Information

11.3.2 Furiex Business Overview

11.3.3 Furiex Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.3.4 Furiex Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.3.5 Furiex Long-acting DPP-4 Inhibitor Drug Revenue by Product in 2024

11.3.6 Furiex Long-acting DPP-4 Inhibitor Drug Revenue by Application in 2024

11.3.7 Furiex Long-acting DPP-4 Inhibitor Drug Revenue by Geographic Area in 2024

11.3.8 Furiex Long-acting DPP-4 Inhibitor Drug SWOT Analysis

11.3.9 Furiex Recent Developments

11.4 Beacon Pharma

11.4.1 Beacon Pharma Corporation Information

11.4.2 Beacon Pharma Business Overview

11.4.3 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.4.4 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.4.5 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue by Product in 2024

11.4.6 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue by Application in 2024

11.4.7 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue by Geographic Area in 2024

11.4.8 Beacon Pharma Long-acting DPP-4 Inhibitor Drug SWOT Analysis

11.4.9 Beacon Pharma Recent Developments

11.5 Kelun Pharmaceutical

11.5.1 Kelun Pharmaceutical Corporation Information

11.5.2 Kelun Pharmaceutical Business Overview

11.5.3 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.5.4 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.5.5 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Product in 2024

11.5.6 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Application in 2024

11.5.7 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue by Geographic Area in 2024

11.5.8 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug SWOT Analysis

11.5.9 Kelun Pharmaceutical Recent Developments

11.6 Haisco Pharmaceutical

11.6.1 Haisco Pharmaceutical Corporation Information

11.6.2 Haisco Pharmaceutical Business Overview

11.6.3 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.6.4 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.6.5 Haisco Pharmaceutical Recent Developments

11.7 Easton Biopharmaceuticals

11.7.1 Easton Biopharmaceuticals Corporation Information

11.7.2 Easton Biopharmaceuticals Business Overview

11.7.3 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.7.4 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.7.5 Easton Biopharmaceuticals Recent Developments

11.8 Baiji Dichang Pharmaceutical

11.8.1 Baiji Dichang Pharmaceutical Corporation Information

11.8.2 Baiji Dichang Pharmaceutical Business Overview

11.8.3 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Features and Attributes

11.8.4 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2020-2025)

11.8.5 Baiji Dichang Pharmaceutical Recent Developments

12 Long-acting DPP-4 Inhibitor DrugIndustry Chain Analysis

12.1 Long-acting DPP-4 Inhibitor Drug Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Long-acting DPP-4 Inhibitor Drug Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Long-acting DPP-4 Inhibitor Drug Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Merck

Takeda Pharmaceutical

Beacon Pharma

Kelun Pharmaceutical

Haisco Pharmaceutical

Easton Biopharmaceuticals

Furiex

Baiji Dichang Pharmaceutical

List of Tables

Table 1. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Long-acting DPP-4 Inhibitor Drug Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Long-acting DPP-4 Inhibitor Drug Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Long-acting DPP-4 Inhibitor Drug Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Long-acting DPP-4 Inhibitor Drug by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting DPP-4 Inhibitor Drug as of 2024)

Table 11. Global Long-acting DPP-4 Inhibitor Drug Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Long-acting DPP-4 Inhibitor Drug Companies Headquarters

Table 13. Global Long-acting DPP-4 Inhibitor Drug Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2026-2031) & (US$ Million)

Table 21. Long-acting DPP-4 Inhibitor Drug High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Long-acting DPP-4 Inhibitor Drug Growth Accelerators and Market Barriers

Table 25. North America Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Long-acting DPP-4 Inhibitor Drug Growth Accelerators and Market Barriers

Table 27. Europe Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Long-acting DPP-4 Inhibitor Drug Investment Opportunities and Key Challenges

Table 31. Central and South America Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Long-acting DPP-4 Inhibitor Drug Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Long-acting DPP-4 Inhibitor Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Merck & Co Corporation Information

Table 35. Merck & Co Description and Major Businesses

Table 36. Merck & Co Product Features and Attributes

Table 37. Merck & Co Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Merck & Co Revenue Proportion by Product in 2024

Table 39. Merck & Co Revenue Proportion by Application in 2024

Table 40. Merck & Co Revenue Proportion by Geographic Area in 2024

Table 41. Merck & Co Long-acting DPP-4 Inhibitor Drug SWOT Analysis

Table 42. Merck & Co Recent Developments

Table 43. Takeda Pharmaceutical Corporation Information

Table 44. Takeda Pharmaceutical Description and Major Businesses

Table 45. Takeda Pharmaceutical Product Features and Attributes

Table 46. Takeda Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Takeda Pharmaceutical Revenue Proportion by Product in 2024

Table 48. Takeda Pharmaceutical Revenue Proportion by Application in 2024

Table 49. Takeda Pharmaceutical Revenue Proportion by Geographic Area in 2024

Table 50. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug SWOT Analysis

Table 51. Takeda Pharmaceutical Recent Developments

Table 52. Furiex Corporation Information

Table 53. Furiex Description and Major Businesses

Table 54. Furiex Product Features and Attributes

Table 55. Furiex Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Furiex Revenue Proportion by Product in 2024

Table 57. Furiex Revenue Proportion by Application in 2024

Table 58. Furiex Revenue Proportion by Geographic Area in 2024

Table 59. Furiex Long-acting DPP-4 Inhibitor Drug SWOT Analysis

Table 60. Furiex Recent Developments

Table 61. Beacon Pharma Corporation Information

Table 62. Beacon Pharma Description and Major Businesses

Table 63. Beacon Pharma Product Features and Attributes

Table 64. Beacon Pharma Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Beacon Pharma Revenue Proportion by Product in 2024

Table 66. Beacon Pharma Revenue Proportion by Application in 2024

Table 67. Beacon Pharma Revenue Proportion by Geographic Area in 2024

Table 68. Beacon Pharma Long-acting DPP-4 Inhibitor Drug SWOT Analysis

Table 69. Beacon Pharma Recent Developments

Table 70. Kelun Pharmaceutical Corporation Information

Table 71. Kelun Pharmaceutical Description and Major Businesses

Table 72. Kelun Pharmaceutical Product Features and Attributes

Table 73. Kelun Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Kelun Pharmaceutical Revenue Proportion by Product in 2024

Table 75. Kelun Pharmaceutical Revenue Proportion by Application in 2024

Table 76. Kelun Pharmaceutical Revenue Proportion by Geographic Area in 2024

Table 77. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug SWOT Analysis

Table 78. Kelun Pharmaceutical Recent Developments

Table 79. Haisco Pharmaceutical Corporation Information

Table 80. Haisco Pharmaceutical Description and Major Businesses

Table 81. Haisco Pharmaceutical Product Features and Attributes

Table 82. Haisco Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. Haisco Pharmaceutical Recent Developments

Table 84. Easton Biopharmaceuticals Corporation Information

Table 85. Easton Biopharmaceuticals Description and Major Businesses

Table 86. Easton Biopharmaceuticals Product Features and Attributes

Table 87. Easton Biopharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. Easton Biopharmaceuticals Recent Developments

Table 89. Baiji Dichang Pharmaceutical Corporation Information

Table 90. Baiji Dichang Pharmaceutical Description and Major Businesses

Table 91. Baiji Dichang Pharmaceutical Product Features and Attributes

Table 92. Baiji Dichang Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Baiji Dichang Pharmaceutical Recent Developments

Table 94. Raw Materials Key Suppliers

Table 95. Distributors List

Table 96. Market Trends and Market Evolution

Table 97. Market Drivers and Opportunities

Table 98. Market Challenges, Risks, and Restraints

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

List of Figures

Figure 1. Long-acting DPP-4 Inhibitor Drug Product Picture

Figure 2. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Weekly Product Picture

Figure 4. Biweekly Product Picture

Figure 5. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Others

Figure 9. Long-acting DPP-4 Inhibitor Drug Report Years Considered

Figure 10. Global Long-acting DPP-4 Inhibitor Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 12. Global Long-acting DPP-4 Inhibitor Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Region (2020-2031)

Figure 14. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Weekly Revenue Market Share by Player in 2024

Figure 17. Biweekly Revenue Market Share by Player in 2024

Figure 18. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2020-2031)

Figure 19. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2020-2031)

Figure 20. North America Long-acting DPP-4 Inhibitor Drug Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) in 2024

Figure 22. North America Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Long-acting DPP-4 Inhibitor Drug Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) in 2024

Figure 29. Europe Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 32. France Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 44. India Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Long-acting DPP-4 Inhibitor Drug Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Long-acting DPP-4 Inhibitor Drug Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) in 2024

Figure 52. Central and South America Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Long-acting DPP-4 Inhibitor Drug Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) in 2024

Figure 58. South America Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Long-acting DPP-4 Inhibitor Drug Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Long-acting DPP-4 Inhibitor Drug Revenue (2020-2025) & (US$ Million)

Figure 64. Long-acting DPP-4 Inhibitor Drug Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions